Risk Factor Profiles Achieved with Medical Therapy in Prevalent Patients with Pulmonary Arterial and Distal Chronic Thromboembolic Pulmonary Hypertension

被引:5
作者
Bartenstein, Philipp [1 ]
Saxer, Stephanie [1 ]
Appenzeller, Paula [1 ]
Lichtblau, Mona [1 ]
Schwarz, Esther I. [1 ]
Ulrich, Silvia [1 ]
机构
[1] Univ Hosp Zurich, Clin Pulmonol, Ramistr 100, CH-8091 Zurich, Switzerland
关键词
Pulmonary arterial hypertension; Chronic thromboembolic pulmonary hypertension; Combination therapy; Risk stratification; Therapeutic goals; BRAIN NATRIURETIC PEPTIDE; PROSPECTIVE REGISTRY; COMBINATION THERAPY; DISEASE MANAGEMENT; BOSENTAN THERAPY; SURVIVAL; INSIGHTS; EPIDEMIOLOGY; MACITENTAN; RIOCIGUAT;
D O I
10.1159/000488000
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The latest pulmonary hypertension (PH) guidelines define therapeutic goals in terms of symptoms, exercise capacity, and haemodynamics for patients with pulmonary arterial hypertension (PAH) and recommend advanced combined medical therapy. For inoperable or post-surgical residual distal chronic thromboembolic PH (CTEPH) medical treatment is similarly advised. Objectives: We analysed whether risk factor goals are achieved and combination therapy is used in prevalent patients with PAH or distal CTEPH. Methods: PAH or distal CTEPH patients who were seen at the University Hospital Zurich during the last year were analysed in terms of demography, clinical data, medication, and therapeutic goals. Achievement of therapeutic goals was defined as New York Heart Association (NYHA) class <= II, N-terminal pro-brain natriuretic peptide (NTproBNP) <300 ng/L, and 6-min walking distance (6MWD) >440 m. Results: A total of 108 PAH patients (age 59 +/- 18 years, 62% female, 64% idiopathic, 36% associated) and 38 distal CTEPH patients (age 69 +/- 14 years, 55% female) were included. They had been diagnosed on average 66 +/- 48 months (+/- SD) previously. The percentage of PAH/CTEPH patients with NYHA <= II was 52/53, respectfully, the percentage of those with NTproBNP <300 ng/L was 61/52, and with 6MWD >440 m 63/50. Overall, 33/31% fulfilled 3 and 29/35% fulfilled 2 of these goals. Regarding therapy, 43% of PAH patients were on double and 10% on triple combination therapy, whereas 16% of distal CTEPH patients were on double and 3% on triple combination therapy. Conclusions: In this real-life cohort of prevalent patients with PAH or distal CTEPH, targeted drug therapy resulted in an achievement of >= 2/3 predefined therapeutic goals in 2/3 of patients. Patients with PAH were more likely to receive combination therapy compared to CTEPH patients. (C) 2018 S. Karger AG, Basel
引用
收藏
页码:127 / 137
页数:11
相关论文
共 47 条
  • [1] Long-term outcome after pulmonary thromboendarterectomy
    Archibald, CJ
    Auger, WR
    Fedullo, PF
    Channick, RN
    Kerr, KM
    Jamieson, SW
    Kapelanski, DP
    Watt, CN
    Moser, KM
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (02) : 523 - 528
  • [2] Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry
    Badesch, David B.
    Raskob, Gary E.
    Elliott, C. Greg
    Krichman, Abby M.
    Farber, Harrison W.
    Frost, Adaani E.
    Barst, Robyn. J.
    Benza, Raymond L.
    Liou, Theodore G.
    Turner, Michelle
    Giles, Scott
    Feldkircher, Kathy
    Miller, Dave P.
    McGoon, Michael D.
    [J]. CHEST, 2010, 137 (02) : 376 - 387
  • [3] Survival in Childhood Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management
    Barst, Robyn J.
    McGoon, Michael D.
    Elliott, C. Gregory
    Foreman, Aimee J.
    Miller, Dave P.
    Ivy, D. Dunbar
    [J]. CIRCULATION, 2012, 125 (01) : 113 - 122
  • [4] Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)
    Benza, Raymond L.
    Miller, Dave P.
    Gomberg-Maitland, Mardi
    Frantz, Robert P.
    Foreman, Aimee J.
    Coffey, Christopher S.
    Frost, Adaani
    Barst, Robyn J.
    Badesch, David B.
    Elliott, C. Gregory
    Liou, Theodore G.
    McGoon, Michael D.
    [J]. CIRCULATION, 2010, 122 (02) : 164 - U138
  • [5] Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension
    Boucly, Athenais
    Weatherald, Jason
    Savale, Laurent
    Jais, Xavier
    Cottin, Vincent
    Prevot, Gregoire
    Picard, Francois
    de Groote, Pascal
    Jevnikar, Mitja
    Bergot, Emmanuel
    Chaouat, Ari
    Chabanne, Celine
    Bourdin, Arnaud
    Parent, Florence
    Montani, David
    Simonneau, Gerald
    Humbert, Marc
    Sitbon, Olivier
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2017, 50 (02)
  • [6] Measurement of quality of life in pulmonary hypertension and its significance
    Cenedese, E.
    Speich, R.
    Dorschner, L.
    Ulrich, S.
    Maggiorini, M.
    Jenni, R.
    Fischler, M.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (04) : 808 - 815
  • [7] The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)
    Cima, Katharina
    Twiss, James
    Speich, Rudolf
    McKenna, Stephen P.
    Gruenig, Ekkehard
    Kaehler, Christian M.
    Ehlken, Nicola
    Treder, Ursula
    Crawford, Sigrid R.
    Huber, Lars C.
    Ulrich, Silvia
    [J]. HEALTH AND QUALITY OF LIFE OUTCOMES, 2012, 10
  • [8] SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY
    DALONZO, GE
    BARST, RJ
    AYRES, SM
    BERGOFSKY, EH
    BRUNDAGE, BH
    DETRE, KM
    FISHMAN, AP
    GOLDRING, RM
    GROVES, BM
    KERNIS, JT
    LEVY, PS
    PIETRA, GG
    REID, LM
    REEVES, JT
    RICH, S
    VREIM, CE
    WILLIAMS, GW
    WU, M
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) : 343 - 349
  • [9] Survival in pulmonary hypertension in Spain: insights from the Spanish registry
    Escribano-Subias, Pilar
    Blanco, Isabel
    Lopez-Meseguer, Manuel
    Jimenez Lopez-Guarch, Carmen
    Roman, Antonio
    Morales, Pilar
    Jesus Castillo-Palma, Maria
    Segovia, Javier
    Gomez-Sanchez, Miguel A.
    Albert Barbera, Joan
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2012, 40 (03) : 596 - 603
  • [10] Fischler M, 2008, SWISS MED WKLY, V138, P371, DOI 2008/25/smw-11914